Fujian Haixi Pharmaceuticals Co., Ltd. (HKG:2637)

Market Cap	11.98B +33.5%
Revenue (ttm)	685.64M +87.6%
Net Income	173.48M +27.9%
EPS	2.31 +14.3%
Shares Out	78.71M
PE Ratio	66.02
Forward PE	52.81
Dividend	n/a
Ex-Dividend Date	n/a

Volume	145,500
Open	149.00
Previous Close	149.50
Day's Range	148.30 - 166.90
52-Week Range	112.50 - 302.40
Beta	n/a
Analysts	Strong Buy
Price Target	292.71 (+92.32%)
Est. Earnings	Nov 27, 2026

About HKG:2637

Fujian Haixi Pharmaceuticals Co., Ltd. engages in research and development, production, and sale of pharmaceutical products in China. The company offers drugs for oncology, ophthalmology, respiratory, digestion, cardiovascular, endocrine, and nervous systems, and inflammation. It also provides pharmaceuticals technical services. In addition, the company offers generic alternatives, such as Anbili, a generic of mosapride citrate tablets; Haihuitong 5mg/10mg and 5mg/20mg, a generic of amlodipine besilate and atorvastatin calcium tablets; Ruiantuo...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2012
• Employees: 200
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2637

Financial Performance

In 2025, HKG:2637's revenue was 582.36 million, an increase of 24.79% compared to the previous year's 466.68 million. Earnings were 177.03 million, an increase of 30.09%.

Financial numbers in CNY

Analyst Summary

According to 3 analysts, the average rating for 2637 stock is "Strong Buy." The 12-month stock price target is $292.71, which is an increase of 92.32% from the latest price.

Price Target

$292.71

(92.32% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 6, 2026

Data Sources Report a data error